These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 17266548)

  • 1. HDL elevators and mimetics--emerging therapies for atherosclerosis.
    Pal M; Pillarisetti S
    Cardiovasc Hematol Agents Med Chem; 2007 Jan; 5(1):55-66. PubMed ID: 17266548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting residual cardiovascular risk: raising high-density lipoprotein cholesterol levels.
    Hausenloy DJ; Yellon DM
    Postgrad Med J; 2008 Nov; 84(997):590-8. PubMed ID: 19103817
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Managing the residual cardiovascular disease risk associated with HDL-cholesterol and triglycerides in statin-treated patients: a clinical update.
    Reiner Z
    Nutr Metab Cardiovasc Dis; 2013 Sep; 23(9):799-807. PubMed ID: 23932901
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
    Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
    Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cholesteryl ester transfer protein (CETP) inhibitors.
    Hunt JA; Lu Z
    Curr Top Med Chem; 2009; 9(5):419-27. PubMed ID: 19519458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport.
    Hersberger M; von Eckardstein A
    Handb Exp Pharmacol; 2005; (170):537-61. PubMed ID: 16596814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The importance of recognizing and treating low levels of high-density lipoprotein cholesterol: a new era in atherosclerosis management.
    Cardenas GA; Lavie CJ; Cardenas V; Milani RV; McCullough PA
    Rev Cardiovasc Med; 2008; 9(4):239-58. PubMed ID: 19122582
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease.
    Chapman MJ
    Pharmacol Ther; 2006 Sep; 111(3):893-908. PubMed ID: 16574234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HDL elevation and lipid lowering therapy: current scenario and future perspectives.
    Chhabria MT; Suhagia BN; Brahmkshatriya PS
    Recent Pat Cardiovasc Drug Discov; 2007 Nov; 2(3):214-27. PubMed ID: 18221121
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed care setting.
    Cziraky MJ; Watson KE; Talbert RL
    J Manag Care Pharm; 2008 Oct; 14(8 Suppl):S3-28; quiz S30-1. PubMed ID: 19891279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. HDL in atherosclerosis: actor or bystander?
    Asztalos BF; Schaefer EJ
    Atheroscler Suppl; 2003 Mar; 4(1):21-9. PubMed ID: 12714034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.
    Hansen MK; McVey MJ; White RF; Legos JJ; Brusq JM; Grillot DA; Issandou M; Barone FC
    J Cardiovasc Pharmacol Ther; 2010 Jun; 15(2):196-202. PubMed ID: 20332533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HDL therapy for cardiovascular diseases: the road to HDL mimetics.
    White CR; Datta G; Zhang Z; Gupta H; Garber DW; Mishra VK; Palgunachari MN; Handattu SP; Chaddha M; Anantharamaiah GM
    Curr Atheroscler Rep; 2008 Oct; 10(5):405-12. PubMed ID: 18706282
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High-Density Lipoprotein-Targeted Therapy and Apolipoprotein A-I Mimetic Peptides.
    Uehara Y; Chiesa G; Saku K
    Circ J; 2015; 79(12):2523-8. PubMed ID: 26548857
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Seeking novel targets for improving in vivo macrophage-specific reverse cholesterol transport: translating basic science into new therapies for the prevention and treatment of atherosclerosis.
    Julve J; Llaverias G; Blanco-Vaca F; Escolà-Gil JC
    Curr Vasc Pharmacol; 2011 Mar; 9(2):220-37. PubMed ID: 21143175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetics of HDL regulation in humans.
    Miller M; Rhyne J; Hamlette S; Birnbaum J; Rodriguez A
    Curr Opin Lipidol; 2003 Jun; 14(3):273-9. PubMed ID: 12840658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. When good cholesterol turns bad: the evolving saga of CETP inhibitors and clinical strategies to elevate high-density lipoprotein.
    Oram JF; Heinecke JW
    Curr Atheroscler Rep; 2007 Dec; 9(6):425-7. PubMed ID: 18377780
    [No Abstract]   [Full Text] [Related]  

  • 18. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.
    Fruchart JC; Duriez P
    Drugs Today (Barc); 2006 Jan; 42(1):39-64. PubMed ID: 16511610
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of cholesteryl ester transfer protein overexpression and inhibition on reverse cholesterol transport.
    Tchoua U; D'Souza W; Mukhamedova N; Blum D; Niesor E; Mizrahi J; Maugeais C; Sviridov D
    Cardiovasc Res; 2008 Mar; 77(4):732-9. PubMed ID: 18056760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Niacin increases HDL by reducing hepatic expression and plasma levels of cholesteryl ester transfer protein in APOE*3Leiden.CETP mice.
    van der Hoorn JW; de Haan W; Berbée JF; Havekes LM; Jukema JW; Rensen PC; Princen HM
    Arterioscler Thromb Vasc Biol; 2008 Nov; 28(11):2016-22. PubMed ID: 18669886
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.